Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products

被引:35
作者
Maeda, Sayaka [1 ]
Matsui, Takanori [1 ]
Ojima, Ayako [1 ]
Takeuchi, Masayoshi [2 ]
Yamagishi, Sho-ichi [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka 8300011, Japan
[2] Kanazawa Med Univ, Med Res Inst, Dept Adv Med, Kanazawa, Ishikawa, Japan
关键词
AGE; RAGE; Oxidative stress; Sulforaphane; Pericytes; Diabetic retinopathy; RETINAL ENDOTHELIAL-CELLS; DIABETIC-RETINOPATHY; INFLAMMATORY REACTIONS; INDUCED INJURY; GROWTH-FACTOR; IN-VITRO; RAGE; AGES; PATHOGENESIS; APOPTOSIS;
D O I
10.1016/j.nutres.2014.08.010
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Advanced glycation end products (AGES) not only inhibit DNA synthesis but also play a role in diabetic retinopathy by evoking apoptosis and inflammation in retinal pericytes via interaction with a receptor for AGE (RAGE). Similarly, sulforaphane, which is a naturally occurring isothiocyanate that is found in widely consumed cruciferous vegetables, protects against oxidative stress induced tissue damage. Therefore, we hypothesized that sulforaphane could inhibit AGE-induced pericytes injury through its antioxidative properties. Advanced glycation end product stimulated superoxide generation as well as RAGE gene and protein expression in bovine-cultured retinal pericytes, and these effects were prevented by the treatment with sulforaphane. Antibodies directed against RAGE also blocked AGE-evoked reactive oxygen species generation in pericytes. Sulforaphane and antibodies directed against RAGE significantly inhibited the AGE-induced decrease in DNA synthesis, apoptotic cell death, and up-regulation of monocyte chemoattractant protein 1 messenger RNA levels in pericytes. For the first time, the present study demonstrates that sulforaphane could inhibit DNA synthesis, apoptotic cell death, and inflammatory reactions in AGE-exposed pericytes, partly by suppressing RAGE expression via its antioxidative properties. Blockade of the AGE-RAGE axis in pericytes by sulforaphane might be a novel therapeutic target for the treatment of diabetic retinopathy. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:807 / 813
页数:7
相关论文
共 39 条
[21]   Nrf2 and NF-κB Modulation by Sulforaphane Counteracts Multiple Manifestations of Diabetic Neuropathy in Rats and High Glucose-Induced Changes [J].
Negi, Geeta ;
Kumar, Ashutosh ;
Sharma, Shyam S. .
CURRENT NEUROVASCULAR RESEARCH, 2011, 8 (04) :294-304
[22]   INHIBITION OF CAPILLARY ENDOTHELIAL-CELL GROWTH BY PERICYTES AND SMOOTH-MUSCLE CELLS [J].
ORLIDGE, A ;
DAMORE, PA .
JOURNAL OF CELL BIOLOGY, 1987, 105 (03) :1455-1462
[23]   Novel inhibitors of advanced glycation endproducts [J].
Rahbar, S ;
Figarola, JL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 419 (01) :63-79
[24]   Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. [J].
Sasaki, N ;
Takeuchi, M ;
Chowei, H ;
Kikuchi, S ;
Hayashi, Y ;
Nakano, N ;
Ikeda, H ;
Yamagishi, S ;
Kitamoto, T ;
Saito, T ;
Makita, Z .
NEUROSCIENCE LETTERS, 2002, 326 (02) :117-120
[25]   THE EFFECT OF LONG-TERM INTENSIFIED INSULIN-TREATMENT ON THE DEVELOPMENT OF MICROVASCULAR COMPLICATIONS OF DIABETES-MELLITUS [J].
REICHARD, P ;
NILSSON, BY ;
ROSENQVIST, U .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :304-309
[26]  
Shapiro TA, 1998, CANCER EPIDEM BIOMAR, V7, P1091
[27]   Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms [J].
Stirban, Alin ;
Gawlowski, Thomas ;
Roden, Michael .
MOLECULAR METABOLISM, 2014, 3 (02) :94-108
[28]  
Stitt AW, 1997, AM J PATHOL, V150, P523
[29]   Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo [J].
Takeuchi, M ;
Makita, Z ;
Bucala, R ;
Suzuki, T ;
Koikie, T ;
Kameda, Y .
MOLECULAR MEDICINE, 2000, 6 (02) :114-125
[30]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853